The Stratµm™ technology revolutionizes injectable pharmaceuticals with delayed release of active pharmaceutical ingredients for true pulse release. A uniform shell contains high loadings of stabilized active ingredients within the aqueous core. Using the Precision Particle Fabrication Platform, we tuned the composition of the shell to release the active after 30 days.
This technology minimizes the number of injections needed by combining a variety of delayed-release microspheres while also enhancing dosage control through uniform, monodisperse microspheres. Such an approach is particularly useful to improve patient compliance by reducing the number of injections (e.g., vaccines or ocular therapies). In addition, the technology enables previously unattainable dosing regimens and pharmacokinetics.
The Stratµm technology produces physically controlled particles using a flexible and cost-effective single-step process with significant advantages over current particle fabrication technologies. Leveraged for injectable pharmaceuticals, the Stratµm technology provides controlled release technology solutions for pulsatile release formulations (no release until monthly time triggers). For pulsatile release drugs, Stratµm™ technology provides an accurate delay before the pulse so that multiple doses can be included in a single injection, which is particularly useful in vaccines and ocular therapies.
The Stratµm technology is cost effective in that it is highly scalable, and has the ability to create microcapsules in a single step. The novel nature of the products and the cost-effective approach lend itself to creating the injectable products of tomorrow. The Stratµm technology is currently being used in a number of therapy areas under development.